RIDDLE&CODE-GMBH
23.8.2022 10:17:11 CEST | Business Wire | Press release
Riddle&Code GmbH is pleased to announce John Calian as the new CEO of the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005122/en/
"I am grateful to have been selected as Riddle&Code's next CEO. We are an organisation led by a purpose – to onboard industrial machines to Web3. It is a privilege to lead a team dedicated to machine-driven token economies, enabling sustainable, green, resilient energy systems," said Calian. "That is the mission of our company. I will do my best to serve the team and our customers by enabling our leaders and people to do their best work."
This decision comes at a momentous time, as Riddle&Code evolves into a product-led service company specialising in Web3 infrastructure and establishing the unique RDDL Network blockchain, which provides the cornerstones for decentralised, secure, and trusted machine economies. Riddle&Code is preparing to be a key contributor to this network and aims to provide the best products, services, and solutions to make this vision flourish.
Working with enterprise partners such as Wien Energie, Daimler Mobility, Evonik, Litebit, and Telekom Innovation Laboratories (T-Labs), Riddle&Code has built an extensive portfolio of blockchain-powered software and hardware products across key industry segments, highlighted by renewable energy producers, electric vehicle manufacturers and large scale energy storage systems providers.
"We are at a natural turning point for the company, and John brings the leadership and expertise needed for Riddle&Code to enter this next phase. Our new purpose is to share our established knowledge and onboard as many industries as possible to Web3 to shape the future of interconnecting token economies with the RDDL Network. This goes way beyond the wildest ambitions of current token projects and energy tech companies." ~ Tom Fürstner, Founder and CTO of Riddle&Code.
The landscape for decentralised infrastructure is rapidly changing, and there has been an increase in demand for blockchain-based software systems due to the ongoing shift towards Web3. This new era requires industries to set up new operating and business models, combining old strengths with a new way of thinking.
Riddle&Code is now focused on being a key player in onboarding industries to Web3 and will provide specific products and services. Co-Founder and outgoing CEO Alexander Koppel will continue as Advisor to the CEO in the future and further support the company's mission. This announcement is the logical next step in the further evolution and continued progress of Riddle&Code and its subsidiary companies.
About Riddle&Code
Riddle&Code is a product-led services company specialising in onboarding industries to Web3. The company is the main driver for a world of interconnected token economies by enabling sustainable, green, and resilient machine industries. Riddle&Code offers various solutions to tailor industry-specific hardware wallets and an application suite to build on decentralised blockchains, mainly contributing to the RDDL Network blockchain protocol.
More information: www.riddleandcode.com
About the RDDL Network
The RDDL Network is a decentralised, industrial machine-powered blockchain protocol that uses a unique Proof-of Productivity (PoP) consensus mechanism that proves identity, data accuracy, and usage for all types of machines. It addresses infrastructure and standards as a whole and is designed to shape the future of interconnected token economies for the fourth industrial revolution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005122/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom